Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience

Although melphalan at a dose of 140 mg/m(2) (MEL140) is an acceptable conditioning regimen for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients, very few studies compared it to the most commonly used dose of 200 mg/m(2) (MEL200). A retrospective review of records of MM p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical transplantation 2016-08, Vol.30 (8), p.894
Hauptverfasser:	Katragadda, Lakshmikanth, McCullough, Lindsay M, Dai, Yunfeng, Hsu, Jack, Byrne, Michael, Hiemenz, John, May, Stratford, Cogle, Christopher R, Norkin, Maxim, Brown, Randy A, Wingard, John R, Chang, Myron, Moreb, Jan S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Dose-Response Relationship, Drug Female Hematopoietic Stem Cell Transplantation - methods Humans Male Melphalan - administration & dosage Multiple Myeloma - surgery Myeloablative Agonists - administration & dosage Retrospective Studies Transplantation Conditioning Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Although melphalan at a dose of 140 mg/m(2) (MEL140) is an acceptable conditioning regimen for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients, very few studies compared it to the most commonly used dose of 200 mg/m(2) (MEL200). A retrospective review of records of MM patients (2001-2010) identified 33 patients who received MEL140 and 96 patients who received MEL200. As expected, significantly higher percentage of patients in the MEL140 arm were >65 years or had cardiac ejection fraction
ISSN:	1399-0012
DOI:	10.1111/ctr.12762